PD12-03 ACTIVE SURVEILLANCE IN 853 MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER
Jonathan Aning(Royal Devon and Exeter Hospital), Martin Gleave(University of British Columbia), Alan So(University of British Columbia), David Harriman, Peter C. Black(University of British Columbia), Michael McKenzie(Provincial Health Services Authority), Larry Goldenberg, Michael Peacock(BC Cancer Agency)
Cited by 0
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532